THOMAS CHEN JOINS THE PKC MANAGEMENT TEAM

INGLEWOOD, CALIFORNIA, May 1, 2007 – Thomas C. Chen, MD, PhD., Associate Professor of Neurological Surgery, Co-Director, USC/Norris Neuro-Oncology Program, Associate Professor of Neurological Surgery and Pathology at the USC Keck School of Medicine, will join the PKC Executive management team as Chief Oncology Officer in June 2007.

Dr. Chen has expressed interest in the PKC Tumor Fighter technology platform because of the applications he envisions in the treatment of glioma brain tumors. Currently, the survivor rate is less than 1% for post-surgical patients. Statistaclly, those who do survive only experience an increase of life span between six months to two years.

Dr. Chen has vast experience as a practitioner in the field of neurosurgery, in particular, the treatment of malignant glioma, one of the most aggressive forms of cancer. Dr. Chen witnesses on a daily basis the suffering and loss of life this form of cancer causes. This has provided him with a strong motivation to join PKC, whose Tumor Fighter Technology (TFT) platform shows great promise for the treatment of this deadly affliction.

Since Dr. Chen joined PKC, he has worked relentlessly to accelerate the development of the TFT platform.

Dr. Chen and PKC Founder Josh Shachar are currently developing the first micropump that will allow the local, internal administration of chemotherapeutic agents as well as the measurement of local conditions and wireless transmission of the data. This will mean an unprecedented capability in any kind of surgical proceedure.

Dr. Chen is currently conducting animal studies at USC to study the effect on malignant gliomas using Avastin, a blockbuster drug developed by Genentech. Avastin, which has shown dramatic results in most applications, has been hampered by side effects in brain cancer treatment. The PKC micropump can markedly reduce side effects by providing local, controllable administration of the medication. Millions of dollars of potential revenue are achievable. As proposed by Dr. Chen, PKC would be the center piece of new collaborative studies in which PKC would be the sponsoring company, USC would provide the venue, and Genentech would be the end user--all funded through a Department of Defense SBIR grant. The first phase would be for $100K and the next phase up to $15MM

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447